{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:02Z","timestamp":1791830402597,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["FAI-2019-0561"],"award-info":[{"award-number":["FAI-2019-0561"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VINNOVA\/Swelife","award":["2017-04936"],"award-info":[{"award-number":["2017-04936"]}]},{"name":"ALF Region Stockholm","award":["20190011"],"award-info":[{"award-number":["20190011"]}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-929972"],"award-info":[{"award-number":["R-929972"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ingegerd Johansson's Fund"},{"name":"Karolinska Institutet Foundation"},{"name":"Swedish Kideny Foundation"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-label therapy for systemic lupus erythematosus (SLE), but data on occurrence and predisposing factors to ADAs in these diseases is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To elucidate the rate of occurrence, and risk factors for ADAs against rituximab in SLE and AAV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ADAs were detected using a bridging electrochemiluminescent (ECL) immunoassay in sera from rituximab-na\u00efve (AAV; <jats:italic>n<\/jats:italic>\u2009=\u200941 and SLE; <jats:italic>n<\/jats:italic>\u2009=\u200962) and rituximab-treated (AAV; <jats:italic>n<\/jats:italic>\u2009=\u200922 and SLE; <jats:italic>n<\/jats:italic>\u2009=\u200966) patients. Clinical data was retrieved from medical records. Disease activity was estimated by the SLE Disease Activity Index-2000 (SLEDAI-2\u00a0K) and the Birmingham Vasculitis Activity Score (BVAS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After first rituximab cycle, no AAV patients were ADA-positive compared to 37.8% of the SLE patients. Samples were obtained at a median (IQR) time of 5.5 (3.7\u20137.0) months (AAV), and 6.0 (5.0\u20137.0) months (SLE). ADA-positive SLE individuals were younger (34.0 (25.9\u201340.8) vs 44.3 (32.7\u201356.3) years, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) and with more active disease (SLEDAI-2\u00a0K 14.0 (10.0\u201318.5) vs. 8.0 (6.0\u201314), <jats:italic>p<\/jats:italic>\u2009=\u20090.0017) and shorter disease duration (4.14 (1.18\u201310.08) vs 9.19 (5.71\u201316.93), <jats:italic>p<\/jats:italic>\u2009=\u20090.0097) compared to ADA-negative SLE. ADAs primarily occurred in nephritis patients, were associated with anti-dsDNA positivity but were not influenced by concomitant use of corticosteroids, cyclophosphamide or previous treatments.<\/jats:p>\n                <jats:p>Despite overall reduction of SLEDAI-2\u00a0K (12.0 (7.0\u201316) to 4.0 (2.0\u20136.7), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), ADA-positive individuals still had higher SLEDAI-2\u00a0K (6.0 (4.0\u20139.0) vs 4.0 (2.0\u20136.0), <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and their B cell count at 6\u00a0months follow-up was higher (CD19\u2009+\u2009% 4.0 (0.5\u201310.0) vs 0.5 (0.4\u20131.0), <jats:italic>p<\/jats:italic>\u2009=\u20090.002). At retreatment, two ADA-positive SLE patients developed serum sickness (16.7%), and three had infusion reactions (25%) in contrast with one (5.2%) serum sickness in the ADA-negative group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In contrast to AAV, ADAs were highly prevalent among rituximab-treated SLE patients already after the first course of treatment and were found to effect on both clinical and immunological responses. The high frequency in SLE may warrant implementations of ADA screening before retreatment and survey of immediate and late-onset infusion reactions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02589-6","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:02:53Z","timestamp":1628845373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-7107","authenticated-orcid":false,"given":"Francesca","family":"Faustini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastya","family":"Kharlamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Ryner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fogdell-Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"issue":"6","key":"2589_CR1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"5","key":"2589_CR2","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390\u2013400.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2589_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"2589_CR4","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2589_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"2589_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2589_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2589_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2589_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713\u201323.","journal-title":"Ann Rheum Dis"},{"key":"2589_CR10","doi-asserted-by":"publisher","unstructured":"Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17(2):81\u201397. https:\/\/doi.org\/10.1038\/s41584-020-00540-8.","DOI":"10.1038\/s41584-020-00540-8"},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fimmu.2017.00500","volume":"8","author":"M Hamze","year":"2017","unstructured":"Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, Pallardy M, Carbonnel F, Spindeldreher S, Mariette X, et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017;8:500.","journal-title":"Front Immunol"},{"issue":"6","key":"2589_CR12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","volume":"59","author":"A Combier","year":"2020","unstructured":"Combier A, Nocturne G, Henry J, Belkhir R, Pavy S, Le Tiec C, Descamps E, Seror R, Mariette X. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology (Oxford). 2020;59(6):1347\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"2589_CR13","doi-asserted-by":"publisher","unstructured":"Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler (Houndmills, Basingstoke, England). 2017. https:\/\/doi.org\/10.1177\/1352458517720044.","DOI":"10.1177\/1352458517720044"},{"issue":"11","key":"2589_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","volume":"76","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2589_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","volume":"78","author":"C Wincup","year":"2019","unstructured":"Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, Mauri C, Consortium A. Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Ann Rheum Dis. 2019;78(8):1140\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2589_CR16","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54(9):2970\u201382.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2589_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271\u20137.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2589_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2589_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3109\/03009742.2016.1138318","volume":"45","author":"A Knight","year":"2016","unstructured":"Knight A, Sundstrom Y, Borjesson O, Bruchfeld A, Malmstrom V, Gunnarsson I. Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol. 2016;45(5):404\u20137.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"2589_CR20","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"12","key":"2589_CR21","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2589_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263\u201372.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2589_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121\u201331.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2589_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. New Engl J Med. 1986;314(10):614\u20139.","journal-title":"New Engl J Med."},{"issue":"11","key":"2589_CR25","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771\u201382.","journal-title":"Ann Rheum Dis"},{"key":"2589_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, Maillot F, Jonville-Bera AP. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59\u201364.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"2589_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1212\/CPJ.0000000000000685","volume":"9","author":"T Holmoy","year":"2019","unstructured":"Holmoy T, Fogdell-Hahn A, Svenningsson A. Serum sickness following rituximab therapy in multiple sclerosis. Neurol Clin Pract. 2019;9(6):519\u201321.","journal-title":"Neurol Clin Pract"},{"key":"2589_CR28","doi-asserted-by":"publisher","first-page":"583560","DOI":"10.3389\/fimmu.2020.583560","volume":"11","author":"N Dunn","year":"2020","unstructured":"Dunn N, Fogdell-Hahn A, Hillert J, Spelman T. Long-term consequences of high titer neutralizing antibodies to interferon-beta in multiple sclerosis. Front Immunol. 2020;11:583560.","journal-title":"Front Immunol"},{"issue":"4","key":"2589_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"issue":"7776","key":"2589_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1595-3","volume":"574","author":"RJM Bashford-Rogers","year":"2019","unstructured":"Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, Thomas DC, Flint SM, Kellam P, Jayne DRW, et al. Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 2019;574(7776):122\u20136.","journal-title":"Nature"},{"issue":"5","key":"2589_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","volume":"13","author":"T Dorner","year":"2011","unstructured":"Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther. 2011;13(5):243.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2589_CR32","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jpba.2011.03.038","volume":"55","author":"S Gupta","year":"2011","unstructured":"Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, Rup B, Song A, Subramanyam M. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878\u201388.","journal-title":"J Pharm Biomed Anal"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02589-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:16:43Z","timestamp":1628846203000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02589-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been conducted in conformity to the approval of the Stockholm Region Ethic Committee (diary numbers 2001\u2013152; 2008\/1143\u201331; 2010\/259\u201332).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the final draft of the article, and approve its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anna Fogdell-Hahn: honoraria, lectures, advisory, boards, unrestricted research grants, BiogenIdec, Pfizer, Roche, Johnson&Johnson and Merck.The other authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}